【摘要】 目的:本研究旨在探讨CD56表达情况与多发性骨髓瘤(MM)患者预后关系。方法:回顾性收集新乡医学院第一附属医院2018年8月至2023年12月收治的125例初诊MM患者的临床资料。将MM患者分为CD56阳性组和CD56阴性组，对比分析两组各项临床参数的差异、无进展生存期(PFS)和总生存期(OS)的差异，并进行Cox单因素及多因素分析。结果:CD56阳性组93例(74.4%),CD56阴性组32例(25.6%);MM患者的中位PFS和OS分别为32个月和未达到，平均PFS和OS分别为39.8个月和52.8个月；CD56阳性组的平均PFS和OS均长于CD56阴性组(平均PFS:42.5个月vs.30.8个月；平均OS:56.2个月vs.42.0个月，均P<0.05)。Cox单因素分析显示，CD56阴性是MM患者PFS、OS短的影响因素(P<0.05)。Cox多因素分析结果显示，CD56阴性是MM患者不良OS的独立危险因素(P<0.05)。结论:CD56阴性与MM患者的不良预后密切相关。更多还原

【Abstract】 Objective: To investigated the relationship between CD56 expression status and prognosis in patients with multiple myeloma(MM). Methods: Clinical data from 125 MM patients admitted to the First Affiliated Hospital of Xinxiang Medical University from August 2018 to December 2023 were retrospectively collected. Patients were divided into CD56-positive group and CD56-negative group. Differences in clinical parameters, progression-free survival(PFS), and overall survival(OS) between the two groups were compared. Univariate and multivariate Cox analysis were performed to identify prognostic factors. Results: Among 125 newly diagnosed MM patients, 93(74.4%) were CD56-positive and 32(25.6%) CD56-negative. The median PFS for all patients was 32 months, while median OS was not reached. The mean PFS and OS were 39.8 months and 52.8 months, respectively. The CD56-positive group showed significantly longer mean PFS and OS compared to the CD56-negative group(PFS: 42.5 vs. 30.8 months; OS: 56.2 vs. 42.0 months; both P<0.05). Univariate Cox analysis indicated CD56 negativity was associated with shorter PFS and OS(both P<0.05). Multivariate analysis confirmed CD56 negativity as an independent risk factor for poor OS(P<0.05). Conclusion: CD56 negativity is closely associated with adverse prognosis in MM patients.更多还原